Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | dopamine receptor D2 | Starlite/ChEMBL | References |
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Homo sapiens | dopamine receptor D4 | Starlite/ChEMBL | References |
Rattus norvegicus | Serotonin 1a (5-HT1a) receptor | Starlite/ChEMBL | References |
Homo sapiens | dopamine receptor D3 | Starlite/ChEMBL | References |
Homo sapiens | dopamine receptor D5 | References | |
Homo sapiens | dopamine receptor D1 | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable isocitrate lyase AceAa [first part] (isocitrase) (isocitratase) (Icl) | 0.0454 | 0.812 | 0.5 |
Mycobacterium tuberculosis | Isocitrate lyase Icl (isocitrase) (isocitratase) | 0.0454 | 0.812 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate lyase AceAb [second part] (isocitrase) (isocitratase) (Icl) | 0.0454 | 0.812 | 0.5 |
Echinococcus multilocularis | serotonin receptor | 0.0167 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE ISOCITRATE LYASE AceA (ISOCITRASE) (ISOCITRATASE) (ICL) | 0.0454 | 0.812 | 1 |
Schistosoma mansoni | biogenic amine (5HT) receptor | 0.0167 | 0 | 0.5 |
Echinococcus multilocularis | serotonin receptor | 0.0167 | 0 | 0.5 |
Echinococcus granulosus | biogenic amine 5HT receptor | 0.0167 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.052 | 1 | 1 |
Mycobacterium ulcerans | isocitrate lyase Icl | 0.0454 | 0.812 | 0.5 |
Mycobacterium ulcerans | isocitrate lyase AceAb | 0.0454 | 0.812 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 89 % | Compound is evaluated for biochemical levels of DOPAC in nonpretreated habituated rats for subcuteneous dose of 100 micromol/kg in rat striatum | ChEMBL. | 8064801 |
Ki (binding) | = 92 nM | Tested for in vitro binding affinity against cloned mammalian dopamine autoreceptor (DA) receptors expressed in CHO-K1 cells [3H]-spiperone as radioligand | ChEMBL. | 8064801 |
Ki (binding) | = 92 nM | Tested for in vitro binding affinity against cloned mammalian dopamine autoreceptor (DA) receptors expressed in CHO-K1 cells [3H]-spiperone as radioligand | ChEMBL. | 8064801 |
Ki (binding) | = 162 nM | Tested for in vitro binding affinity against cloned mammalian dopamine autoreceptor (DA) receptors expressed in CHO-K1 cells using [3H]-U-86,170 as radioligand | ChEMBL. | 8064801 |
Ki (binding) | = 162 nM | Tested for in vitro binding affinity against cloned mammalian dopamine autoreceptor (DA) receptors expressed in CHO-K1 cells using [3H]-U-86,170 as radioligand | ChEMBL. | 8064801 |
Ki (binding) | > 217 nM | Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand | ChEMBL. | 8064801 |
Ki (binding) | > 217 nM | Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand | ChEMBL. | 8064801 |
Ki (binding) | = 1320 nM | Tested for affinity against striatal dopamine autoreceptor (DA) D2 receptors using [3H]-spiperone as raidoligand in rats. | ChEMBL. | 8064801 |
Ki (binding) | = 1320 nM | Tested for affinity against striatal dopamine autoreceptor (DA) D2 receptors using [3H]-spiperone as raidoligand in rats. | ChEMBL. | 8064801 |
Ki (binding) | = 1600 nM | Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in homogenized rat brain tissue | ChEMBL. | 8064801 |
Ki (binding) | = 1600 nM | Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in homogenized rat brain tissue | ChEMBL. | 8064801 |
LMA (functional) | = 152 | Evaluated for locomotor activity in nonpretreated habituated rats at 100 micromol/kg of subcuteneous dose | ChEMBL. | 8064801 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.